Telix Pharmaceuticals Ltd — Director's Dealing 2021

May 11, 2021

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity Telix Pharmaceuticals Limited ABN 85 616 620 369

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Christian Behrenbruch
Date of last notice	12 May 2020

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest	Direct Interest
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.
Date of change	12 May 2021
No. of securities held prior to change	24,675,000 fully paid ordinary shares (Indirect interest) 400,000 share options with an exercise price of $1.09 per option and an expiry date of 24 January 2023. Options vest on 24 January 2022 (Direct interest). (TLXO004) 200,000 share options with an exercise price of $2.23 per option and an expiry date of 12 January 2024. Options vest on 13 January 2023. Options granted following shareholder approval at the AGM held 12 May 2020. (TLXO006)

• See chapter 19 for defined terms.

01/01/2011

Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

Class	Share Options (TLXO009)
Number acquired	100,708 share options with an exercise price of $4.38 per option and an expiry date of 26 January 2026. Options vest upon achievement of $100M in cumulative revenue from product sales. Options allotted following shareholder approval at the AGM held 12 May 2020. (TLXO009).
Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Options issued for nil consideration following shareholder approval at the AGM held 12 May 2021.
No. of securities held after change	24,675,000 fully paid ordinary shares (Indirect interest) 400,000 share options with an exercise price of $1.09 per option and an expiry date of 24 January 2023. Options vest on 24 January 2022. (Direct interest) (TLXO004) 200,000 share options with an exercise price of $2.23 per option and an expiry date of 12 January 2024. Options vest on 13 January 2023. Options granted following shareholder approval at the AGM held 12 May 2020. (Direct interest) (TLXO006) 100,708 share options with an exercise price of $4.38 per option and an expiry date of 26 January 2026. Options vest upon achievement of $100M in cumulative revenue from product sales. Options allotted following shareholder approval at the AGM held 12 May 2020. (Direct interest) (TLXO009).
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Options issued following shareholder approval at the AGM held 12 May 2021.

Part 2 – Change of director’s interests in contracts – NOT APPLICABLE

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

• See chapter 19 for defined terms.

Appendix 3Y Page 2

01/01/2011

Appendix 3Y Change of Director’s Interest Notice

Detail of contract Nature of interest Name of registered holder (if issued securities) Date of change No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed Interest acquired Interest disposed Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation Interest after change

Part 3 –[+] Closed period

Part 3 –+Closed period
Were the interests in the securities or contracts detailed above traded during a+closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

• See chapter 19 for defined terms.

01/01/2011

Appendix 3Y Page 3